How, if at all, does concurrent TP53 mutation status guide first-line treatment selection between osimertinib alone and osimertinib plus chemotherapy for advanced nonsquamous NSCLC with an EGFR-sensitizing mutation?
Does the subtype of EGFR mutation affect your decision?